ALEBUND-B (HKEX: 09637) commenced trading on the main board of the Hong Kong Stock Exchange today, marking its debut as the first purely nephrology-focused 18A biotech company in the Hong Kong market.

At the time of writing, the stock is trading at HK$44.8, surging over 98%, giving the company a market capitalisation exceeding HK$150 billion.

Beyond the initial share price surge, the company holds significant industry value as a case study.

The domestic chronic disease management landscape is undergoing a systemic shift from "single-treatment" approaches towards "full-course outcome delivery." ALEBUND-B has positioned itself at the heart of this industry evolution.

It has not followed the traditional biotech linear path of solely developing drugs and awaiting approval.

Instead, it has anchored itself in the vertical nephrology field, constructing a comprehensive system encompassing a "full-course drug portfolio, pre-established commercial channels, and an extensible service loop."

This strategy charts a path of low volatility and high predictability for a specialised biotech firm.

To a certain extent, its listing is both a milestone for the nephrology innovation drug sector and a market test for vertical chronic disease management models transitioning from concept to industrial implementation.

Strategic Selection: Securing a Dominant Position in the Blue Ocean of Chronic Disease Evolution

Intensified competition in China's innovative drug industry over recent years stems largely from homogeneous competition in crowded therapeutic areas, leading to pricing pressures from national reimbursement negotiations and diminishing marginal returns on R&D investment.

From a broader chronic disease industry perspective, a deeper paradigm shift is underway.

Chronic kidney disease, the world's third-largest chronic disease, represents a blue ocean sector that has been long underestimated by major pharmaceutical companies yet has urgent unmet needs.

Statistics indicate over 300 million chronic disease patients in China, with approximately 124 million CKD patients domestically and over 800 million globally.

However, the nephrology field has seen a gap of over 50 years without disease-modifying therapies and more than a decade without a major novel drug for complications, highlighting a significant mismatch between clinical need and effective supply.

Critically, the challenges in CKD management are more pronounced than in many other chronic conditions.

The disease course spans over a decade, involves multiple complications, and suffers from poor patient adherence.

Traditional single-visit outpatient models lack long-term post-discharge intervention mechanisms, leading to high patient attrition rates and long-term control rates for key indicators like serum phosphorus and anaemia remaining below 25%.

As chronic disease industry research commonly notes, the first-generation model focused on "selling tools and services," merely identifying problems while leaving the difficult task of "long-term execution" to patients, ultimately failing to deliver meaningful health outcomes.

The core of second-generation chronic disease management shifts from "monitoring-driven" to "outcome-responsible," delivering verifiable health benefits through standardised intervention systems.

ALEBUND-B's strategic positioning aligns precisely with this underlying industry logic.

It has not pursued a scattered portfolio of single nephrology drugs but has built a top-down, full-course product matrix covering "complication control — disease modification — functional cure," addressing CKD patient needs from early to end-stage disease.

In the hyperphosphatemia sub-field, the only two investigational novel molecules in global clinical development, AP301 and AP306, both belong to ALEBUND-B.

With complementary mechanisms and tiered positioning, they form a near-monopolistic barrier in this segment.

This "strong positioning within a slow-moving sector" provides biotech firms with a solid foundation.

Nephrology patients often require medication for years to over a decade, offering stable adherence, high refill rates, and greater lifetime value per patient compared to many oncology indications.

Furthermore, the sector faces less intense competition, reducing exposure to fierce price wars and facilitating a more stable, predictable cash flow model.

More importantly, a complete drug portfolio lays the essential product foundation for extending into full-course services and moving towards an "outcome-oriented" chronic disease management model.

Model Innovation: Pre-emptive Commercialisation and the Potential of a "Disease Management" Closed Loop

A common challenge for traditional 18A companies is their typical growth path: listing without products, revenue, or a commercial team, relying entirely on financing for R&D.

After product approval, building a sales system from scratch often takes 3-5 years to reach breakeven, with valuations fluctuating wildly around clinical milestones and weak risk resilience.

ALEBUND-B has diverged from this linear "R&D — burn cash — await approval — then commercialise" path by adopting a "pre-emptive commercialisation" strategy.

Before the launch of its core proprietary products, it first established a commercial foundation through a mature product.

The company entered the Chinese nephrology market three years early by in-licensing Roche's long-acting erythropoiesis-stimulating agent, Mircera®.

This product, the world's only once-monthly long-acting EPO, generated revenue of RMB 6.525 million in its first launch year in 2024, soaring to RMB 30.556 million in 2025, a year-on-year increase of 368%.

It now covers over 300 hospitals in more than 50 cities across China, is included in the National Reimbursement Drug List, and remains in a rapid uptake phase.

The value of this move extends far beyond providing cash flow.

First, it validates the company's capabilities in nephrology specialty market access, medical promotion, and commercial execution, demonstrating to the market that the team can successfully commercialise products, moving beyond a paper-based R&D narrative.

Second, it has established a mature nephrology specialty sales network in advance.

When AP301 and AP306 are approved, this existing channel can be directly leveraged, significantly shortening the new product uptake cycle, reducing the sales expense ratio, and creating a synergistic effect of "one product paving the way, multiple products monetising."

Third, the growing revenue stream helps hedge against R&D investment volatility, providing the company with stronger risk resilience and strategic stability, especially in weaker market conditions.

The deeper potential lies in this channel network's capacity to extend into full-course disease management.

Public hospitals are transitioning from a "disease-centered" to a "health-centered" model, creating a strong need within nephrology departments for standardised, full-course management.

Tasks like long-term patient follow-up, complication monitoring, and dietary and medication guidance are complex, straining hospital resources and creating demand for standardised, implementable chronic disease management solutions.

With its existing access to nephrology departments in over 300 hospitals, ALEBUND-B possesses a natural advantage for deploying specialised chronic disease management.

In the future, leveraging its full-course drug portfolio, it could layer on stratified intervention pathways and AI-powered follow-up systems to provide hospitals with specialised, full-course CKD management services.

This could create a complete loop from standardised inpatient treatment to post-discharge home monitoring, medication reminders, and early complication screening.

This model aligns with the "health outcome-oriented" direction of chronic disease industry evolution, potentially improving key indicator control rates like serum phosphorus and haemoglobin.

It could also improve product adherence and prescription renewal rates, expanding the lifetime value per patient from single-product consumption to the comprehensive value of full-course management, building user loyalty and competitive barriers far exceeding those of traditional pharmaceutical companies.

Coupled with its four-tiered pipeline structure—"commercialised product, registration-stage product, mid-stage clinical assets, and early-stage proprietary pipeline"—the company has clear clinical or commercial milestones annually, avoiding the extreme risk of many biotechs betting on a single product's success or failure.

A New Approach to Global Expansion: A Balanced Strategy for Chronic Disease Innovation

While global expansion for Chinese innovative drugs has been discussed for years, it often faces two extremes: either fully funding costly and high-risk global Phase III trials, or simply licensing out rights in a one-off deal, sacrificing long-term growth potential.

ALEBUND-B's differentiated approach involves a stratified globalisation strategy tailored to pipelines at different stages and with different strategic positioning, maximising long-term value while controlling risk.

For its high-certainty, mature core asset AP301, the company retains global rights, advancing multi-center Phase III trials in China and the US simultaneously, with plans to submit marketing applications to both the NMPA and FDA, preserving long-term benefits from global markets.

For AP306, a novel-mechanism asset requiring significant overseas industry resources, it adopted a capital-light "industry partnership and risk-sharing" model.

It partnered with R1 Therapeutics, backed by US dialysis giants DaVita and U.S. Renal Care, where the partner bears major overseas clinical development costs and provides end-channel resources.

ALEBUND-B retains full rights for Greater China while receiving milestone payments, tiered royalties, and equity value appreciation in the joint venture.

This model's value lies not only in cost-sharing but also in directly binding key overseas end-market industry resources.

DaVita and U.S. Renal Care collectively hold over 50% of the US dialysis market share, which can significantly accelerate clinical trial enrolment and post-approval market access—barriers difficult for a biotech alone to overcome.

More importantly, it provides a replicable template for the global expansion of Chinese chronic disease innovation drugs.

Compared to oncology drugs with complex indications and significant regional variations in treatment standards, chronic diseases like CKD have more uniform global treatment pathways, large patient populations, and clearer clinical endpoints, offering a stronger foundation for globalisation.

The "product + channel + industry capital" partnership model allows for greater sharing of long-term global market benefits than simple out-licensing and better aligns with the long-term management nature of chronic diseases.

Post-Listing Trajectory: From Nephrology Drug Company to Full-Course Management Platform

Listing on the Hong Kong Stock Exchange represents a new starting point for ALEBUND-B's growth.

Following its current pipeline progression and industry extension path, the company's value realisation roadmap appears clear.

In the short term (1-2 years), the company will enter a critical clinical validation window for multiple pipelines.

Beyond advancing the registration and approval process for its core product AP301, proof-of-concept data readouts for AP303 (a dual PPAR agonist) and AP308 (an IgA protease) are expected next year, validating their potential in CKD disease modification and IgA nephropathy functional cure, respectively.

Concurrently, global Phase IIb data for AP306 will serve as a key indicator of its global competitiveness.

With multiple pipelines entering critical validation phases, the company's valuation logic may shift from being "driven by a single core product" to being "driven by a multi-product portfolio."

In the medium term (3-5 years), as core products like AP301 and AP306 progress towards approval and commercialisation, the nephrology commercial network built via Mircera® will enter a phase of reuse.

The synergistic effect of its tiered pipeline layout could materialise, with one product paving the way for others to monetise successively.

Simultaneously, leveraging its existing hospital coverage and specialty channel advantages, the company could gradually explore full-course nephrology management services, extending from pure drug supply to long-term patient management.

In the long term, the large-scale uptake of AP301 will be a core driver of long-term value release.

Looking further ahead, the ultimate competition in chronic disease management is evolving from single-product supply to a contest of systemic capabilities involving "technology + platform + ecosystem," with the highest industry value shifting towards the central "behavioural engine" and the "health operating system" responsible for outcomes.

With its full-course product portfolio and specialty channel network, ALEBUND-B has the opportunity to grow into a full-course management platform for the vertical nephrology field, taking responsibility for patients' long-term kidney function outcomes.

This vertical closed-loop model offers stronger professional barriers than general chronic disease management platforms and possesses broader revenue potential and a higher valuation ceiling than traditional pharmaceutical companies.

Eight years after the implementation of the 18A rules, the industry is undergoing a profound value reassessment.

Capital is no longer rewarding empty target stories but is concentrating on "clear sector barriers, verifiable commercialisation capabilities, and sustainable growth paths."

The value of ALEBUND-B extends beyond its own growth potential; it opens up new perspectives for the industry.

Opportunities in innovative drugs are not confined to crowded, popular sectors, and the future of chronic disease management is more than just the simple addition of tools and services.

Perhaps a path of deep specialisation, building closed loops, and steadily delivering value can chart a higher-quality course for growth.